KEQU KEWAUNEE SCIENTIFIC CORP /DE/
No recent data for KEQU. Our end-of-day feed has carried no price for this security since 2026-09-02, and we found no SEC delisting or deregistration filing that would explain it — so this reflects the coverage of our data source. The security may still be trading, and quotes may be available elsewhere. Company filings and reported financials on this page are unaffected.
Updated
Healthcare · Laboratory Apparatus & Furniture
KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) is a healthcare company in the Laboratory Apparatus & Furniture industry, with a market capitalization of $107 million. Price data for KEQU is unavailable — our feed has carried no quote since 2026-09-02. KEQU trades at a price-to-earnings ratio of 13.04, below the Healthcare median of 27.46. Net profit margin is 3.0%, above the peer median of -1.5%. Revenue grew 17.3% year over year. The shares yield 2.0% in dividends.
Chart hidden: no price data for KEQU since 2026-09-02. Company filings and financials below are current.
Financials
Latest reported annual period ending 2026-07-31 · SEC EDGAR/XBRL.
KEQU Dividend History
| Fiscal year end | Total dividends paid | Per share* | Payout ratio |
|---|---|---|---|
| 2020-04-30 | $1M | $0.00 | — |
| 2019-04-30 | $2M | $0.00 | 133% |
*Per share derived as total dividends paid ÷ weighted diluted shares (SEC EDGAR/XBRL annual cash-flow facts). Reported history — not a forecast of future dividends.
Compare payers on the highest-dividend-yield screener.
Recent earnings
| Period | EPS (diluted) | Reported |
|---|---|---|
| Q1 2027 | $0.58 | 2026-09-11 |
| FY 2026 | $3.22 | 2026-06-26 |
| Q3 2026 | $2.09 | 2026-03-13 |
| Q2 2026 | $1.86 | 2025-12-12 |
| Q1 2027 | $1.04 | 2026-09-11 |
| FY 2026 | $3.83 | 2026-06-26 |
Healthcare peers
KEQU vs 14 sector peers (Healthcare), by market cap. Updated
| LLY | Lilly (Eli) | $1.09T | 40.86 | 13.70 | 33.5% | -0.02% |
| JNJ | Johnson & Johnson | $670.6B | 31.88 | 6.85 | 21.5% | +1.04% |
| ONC | Beone Medicines Ltd. | $535.9B | 817.25 | 87.43 | 10.7% | +0.23% |
| ABBV | AbbVie | $459.8B | 72.87 | 7.14 | 9.8% | -0.57% |
| MRK | Merck | $375.8B | 118.44 | 5.65 | 4.8% | +0.44% |
| AMGN | Amgen | $240.1B | 27.47 | 6.30 | 23.0% | +0.31% |
| TMO | Thermo Fisher Scientific | $228.7B | 32.82 | 4.94 | 15.0% | +1.66% |
| KLAC | KLA Corporation | $225.9B | 46.76 | 16.64 | 35.6% | +0.37% |
| ABT | Abbott Laboratories | $189.5B | 30.20 | 4.20 | 13.9% | -1.50% |
| GILD | Gilead Sciences | $187.5B | -57.87 | 6.16 | -10.6% | +1.09% |
| PFE | Pfizer | $164.2B | 37.91 | 2.58 | 6.8% | -0.76% |
| DHR | Danaher Corporation | $148.3B | 37.05 | 5.91 | 15.9% | +0.49% |
| VRTX | Vertex Pharmaceuticals | $141.5B | 32.11 | 11.24 | 35.0% | +0.24% |
| BMY | Bristol Myers Squibb | $139.1B | 14.98 | 2.83 | 18.9% | +0.62% |
Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.